Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia.

Introduction Our study was designed to investigate the safety and efficacy of combined autologous bone marrow mononuclear cell (MNC) and gene therapy in comparison to conventional drug therapy in patients with critical limb ischemia (CLI).